Apr 28, 2023 / NTS GMT
Alfred Chan - Principal Investor Relations - IR
Good morning, everyone. The clock has now ticked past 11:00 AM, so we'll get started with today's special investor briefing with Pharmaxis CEO Gary Phillips, who will provide an update on the clinical trial program and the exciting FDA developments. My name is Alfred, and I'm part of the Pharmaxis Investor Relations team, and I'll assist Gary with running the briefing today.
I'll just quickly run through some of the formalities. After the presentation, Gary will be taking questions from attendees. (Event Instructions)
It's obviously a very busy day on the ASX today, especially being the short week. So Gary has been very generous with his time to present the quarterly activities and plans going forward. I won't take up anymore of your time. Gary, let me hand over to you.
Gary Phillips - Pharmaxis Limited - CEO
Thank you, Alfred, and morning, everybody. Yeah, I don't mind spending my time with you. This is a particular time in the lifecycle of Pharmaxis where we're ahead of some clinical trial results
Pharmaxis Ltd To Provide an Update on Company Recent Updates and Future Plan Transcript
Apr 28, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers